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The US FDA and the European Medicines Agency have
recently proposed the implementation of the Quality by
Design (QbD) paradigm to the manufacture of biophar-
maceuticals. Its implementation requires the use of all
available knowledge of a given product, including the
parameters that affect its quality, for the design, optimi-
zation and control of the manufacturing process. The
goal is to ensure that quality is built into the product at
every stage of the manufacturing process. Most licensed
monoclonal antibodies (mAbs) are based on the immu-
noglobulin G isotype and contain a consensus N-linked
glycosylation site on the Cg2 domains of their heavy
chains. Studies have found that the oligosaccharides
attached to this site dramatically influence the efficacy
of mAbs as therapeutics either by reducing their serum
half-life or by directly affecting the mechanisms they
trigger in vivo[1,2], thus defining glycosylation as a criti-
cal quality attribute of mAbs under the QbD scope. It
has been recently proposed that detailed mathematical
models will play a critical role in the design, control and
optimization of biopharmaceutical manufacturing pro-
cesses under the QbD scope [3]. To our knowledge,
there are currently no mathematical models that relate
mAb glycosylation with cell culture conditions.
Several reports have shown that glycosylation is
directly affected by the intracellular availability of
nucleotide sugar donors (NSDs) [4] which are the co-
substrates for the glycosylation reactions that occur in
the Golgi apparatus. During culture, cells synthesize all
the relevant NSDs from glucose through the nucleotide
sugar metabolic pathway. In an effort to relate process
conditions with mAb glycosylation, we have generated a
dynamic mathematical model for this metabolic path-
way. The NSD pathway described in KEGG [5] was
used as the starting point. In the full pathway, four
potential carbon sources are converted into the eight
main NSDs (UDP-GlcNAc, UDP-Glucose, UDP-Galac-
tose, UDP-GalNAc, UDP-GlcA, GDP-Man, GDP-Fuc
and CMP-Neu5Ac) through 31 enzymatic reactions.
However, many of the intermediary species are difficult
to measure throughout the course of cell culture. For
this reason, the kinetic model was reduced based on the
methodology described by Nolan and Lee [6] whereby
sequential reactions along different branches of the
pathway were lumped into single reactions. As an addi-
tional simplification, glucose was considered as the only
carbon source for the pathway. In order to relate NSD
metabolism with macroscopic cell culture variables, a
model for cell growth, nutrient depletion, metabolite
accumulation and product secretion was formulated
based on conventional Monod kinetics. Both models
were linked by defining the intracellular glucose accu-
mulation needed for the NSD model as a function of
the glucose maintenance energy term (ms,glc) from the
cell culture model; the outlet of NSDs from the cells
was associated to the product secretion rate.
In order to estimate the unknown parameters of the
combined model, experimental data from Kochanowski
and collaborators [7] was used. First, the parameters
from the macroscopic model were estimated from the
data, including the maintenance energy term for glu-
cose. The results are shown in panels A, B, C and D of
Figure 1. Once the cell culture data was reproduced
accurately with the estimated parameters, the unknown
kinetic parameters from the NSD component of the
model were estimated with the intracellular NSD data1Department of Chemical Engineering, Imperial College London, London,
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from Kochanowski et al. [7]. These results are shown in
panels E, F, G and H of Figure 1.
Figure 1 shows that, overall, the model reproduces the
experimental data accurately. The only exceptions are
the UDP-GlcNAc concentration profiles for both culture
media and the UDP-GalNAc profiles for the SF-RPMI
medium. In the case of UDP-GlcNAc, the model pre-
dicts higher accumulation of this NSD towards the end
of the data set, whereas the experimental data suggests
that the profile flattens out. It is likely that the model
Figure 1 Model reproduction of the experimental data. A, B, C and D show reproduction of viable cell counts (Xv), dead cell counts (Xd),
glucose, glutamine, ammonia and product concentrations in conventional culture media (SF-RPMI) and optimized chemically defined media (PF-
BDM). E, F, G and H show reproduction of intracellular NSD concentrations.
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overestimates UDP-GlcNAc accumulation because
experimental data for CMP-Neu5Ac was unavailable
and therefore, this NSD was not considered within the
model. From the reduced metabolic network for NSDs,
it is known that CMP-Neu5Ac is produced from UDP-
GlcNAc. If CMP-Neu5Ac is not considered within the
model, it is natural that the model will predict addi-
tional accumulation of UDP-GlcNAc. In the case of
UDP-GalNAc for the SF-RPMI medium, overaccumula-
tion for this NSD is also predicted by the model. It is
possible that this is due to the excess accumulation of
UDP-GlcNAc. From the metabolic network, it is known
that UDP-GalNAc is directly synthesized from UDP-
GlcNAc. If the model predicts higher accumulation of
the latter, it will certainly predict higher UDP-GalNAc
accumulation as well.
To our knowledge, the model presented in this work
is the first to link cell culture variables with intracellular
metabolic processes through the glucose maintenance
energy term (ms,glc). Furthermore, it is the first model to
relate cell culture variables with intracellular NSD con-
centrations and the results show that it is capable of
reproducing experimental data accurately. However, in
order to achieve better reproduction of experimental
data and obtain higher confidence in the estimated para-
meters, additional experimental data is needed. Specifi-
cally, the concentration profiles of GDP-Fuc and CMP-
Neu5Ac throughout cell culture would lead to improved
reproduction of experimental data and predictive cap-
abilities of the model. Furthermore, fed-batch cultures
are also necessary to validate the model and its
parameters.
Once validated with additional data, our mathematical
model for NSD metabolism, can be coupled to a model
for Golgi N-linked glycosylation. This combined model
would generate a direct link between extracellular glu-
cose concentration, which is a readily measurable pro-
cess variable, and protein glycosylation. Such a
combined model has great potential for the design, con-
trol and optimization of manufacturing processes that
produce mAbs with built in glycosylation-associated
quality as proposed under the QbD paradigm.
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